Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FATE-NK100 |
Synonyms | |
Therapy Description |
FATE-NK100 are donor-derived natural killer cells, which may induce cell death, and result in increased generation of inflammatory cytokines, thereby mediating an immune response against cancer cells (Cancer Res 2017;77(13 Suppl):Abstract nr 3752). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FATE-NK100 | FATE NK100 | FATE-NK100 are donor-derived natural killer cells, which may induce cell death, and result in increased generation of inflammatory cytokines, thereby mediating an immune response against cancer cells (Cancer Res 2017;77(13 Suppl):Abstract nr 3752). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03081780 | Phase I | FATE-NK100 | Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML | Completed | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |